Globus Medical, Inc.
GMED Large CapHealthcare · Medical Devices
Mis à jour: Jun 18, 2026, 22:21 UTC
Price Chart
Indicateurs clés
Valuation Analysis
About the Company
Globus Medical, Inc. en bref
Globus Medical, Inc. (GMED) is currently trading at 69,06 € with a market capitalization of 9,4 Md €. The trailing P/E ratio stands at 18.51x, with a forward P/E of 15.4x. The 52-week range spans from 45,15 € to 88,40 €; the current price is 21.9% below the yearly high. Year-over-year revenue growth stands at +27.0%. The net profit margin stands at 18.92%.
💰 Dividende
Globus Medical, Inc. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.
📊 Avis des analystes
11 analystes évaluent Globus Medical, Inc. (GMED) au consensus : Acheter. L'objectif de cours moyen est de 94,71 €, soit un potentiel de +37.13% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 75,84 € à 106,36 €.
Globus Medical, Inc. : la thèse d'investissement en détail
Globus Medical, Inc. (GMED) operates in the Healthcare — specifically Medical Devices — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.
Le scénario haussier
Top-line momentum is unusually strong with revenue expanding 27% year-over-year, a pace that puts the company well above the market average and signals genuine demand traction rather than mere cyclical tailwind. With a gross margin near 68.49%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Free cash flow is positive and net margins stand at 18.92%, meaning reported earnings translate into real cash that can fund buybacks, dividends or strategic acquisitions.
Valorisation en contexte
The PEG ratio at 1.49 sits in the reasonable zone — the price tag is roughly aligned with the company's growth profile, neither punishing nor euphoric.
À surveiller
- The forward P/E of 15.4x is meaningfully below the trailing 18.51x — analysts expect earnings to step up; the next earnings release is the test.
- The analyst consensus price target implies 37.13% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.
Thèse d'investissement : forces et faiblesses
- Forte croissance du CA de 27% sur un an
- Marge brute élevée de 68.49% — signe d'un pouvoir de fixation des prix
- Consensus des analystes : Buy
- Bilan solide avec faible endettement (D/E 2.45)
- Free cash flow positif
Aucun signal d'alerte significatif dans les indicateurs actuels.
Aperçu technique
The price is in a transition zone relative to the moving averages — no clear signal.
Profil de risque
The data points to relatively defensive market behavior.
Trading Data
Related Stocks in the Same Sector
More Santé stocks
Top peers in the same sector — ranked by market cap.
Where can I buy Globus Medical, Inc.?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
Live Market Data
Real-time chart, financials, earnings, analysts, insider trades, events & news